| 1.87 0.1 (5.65%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.38 | 1-year : | 2.66 |
| Resists | First : | 2.03 | Second : | 2.27 |
| Pivot price | 1.9  |
|||
| Supports | First : | 1.64 | Second : | 1.37 |
| MAs | MA(5) : | 1.79 |
MA(20) : | 1.94 |
| MA(100) : | 1.93 |
MA(250) : | 2.47 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 29 |
D(3) : | 20.3 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 4.2 | Low : | 1.47 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MREO ] has closed above bottom band by 42.5%. Bollinger Bands are 15.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.93 - 1.94 | 1.94 - 1.95 |
| Low: | 1.76 - 1.77 | 1.77 - 1.78 |
| Close: | 1.85 - 1.87 | 1.87 - 1.88 |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Mon, 10 Nov 2025
Mereo (MREO) Prepares for Setrusumab Study Results and New Partn - GuruFocus
Mon, 10 Nov 2025
Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights - Yahoo Finance UK
Mon, 10 Nov 2025
Mereo BioPharma (NASDAQ: MREO) reports $48.7M cash, runway into 2027 amid setrusumab work - Stock Titan
Fri, 07 Nov 2025
Mereo BioPharma Group PLC expected to post a loss of 2 cents a share - Earnings Preview - TradingView
Tue, 12 Aug 2025
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 159 (M) |
| Held by Insiders | 5.0235e+008 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 11,040 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.401e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 950.7 % |
| Return on Equity (ttm) | -35.2 % |
| Qtrly Rev. Growth | 500000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -191.31 |
| EBITDA (p.s.) | 943590 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 2.14 |
| Dividend | 0 |
| Forward Dividend | 1.116e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|